+6504738654

T-048 P.028/029 F-406

Form 1449 (modified)	Filing Date:	November 19, 1997	U.S.S.N. 08/974,584
	inventors:	Cech et al.	
Information Disclosure Statement By Applicant	Title:	Amino Acid Motifs that Identify Telomerase Reverse Transcriptase	
	l		Group: 1634
	Docket:	018/206P2	Examiner: Carla J. Myers, Ph.D.

#### **U.S. Patent Documents**

Examiner Initial	Ref.	Patent - No.	Issue or Pub Date	inventors:	Assignee:	Title:
Ch		6,166,178	12/26/2000	Cech et al.	Regents U. CO & Geron Corp.	Telomerase Catalytic Subunit
1		6,337,200	1/8/2002	Morin	Geron Corp.	Human Telomerase Catalytic Subunit Variants
		6,627,619	9/30/2003	Cech et al.	Regents U. CO & Geron Corp.	Methods for Inhibiting Telomerase Using Antisense Oligonucleotides
		6,808,880	10/26/2004	Cach et al.	Regents U. CO & Geron Corp.	Method for Identifying Nucleotide Sequences Encoding Telomerase
		6,921,664	7/26/2005	Cech et al.	Regents U. CO & Geron Corp.	Vectors for Expressing Telomerase Reverse Transcriptase
		6,927,285	8/9/2005	Cech et al.	Regents U. CO & Geron Corp.	Gene for Human Telomerase Reverse Transcriptase and Telomerase Variants
Cr		7,005,262	2/28/2006	Cech et al.	Regents U. CO & Geron Corp.	Methods for Detecting Nucleic Acids Encoding Human Telomerase Reverse Transcriptase

Examiner	Date Considered
Carlemys	5-16-06

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Page 1

OIP	Ever
OLI OB	Substitute for for
CONTA TRA	PNFORM

Substitute for form 1449A/PTO

# MFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

	Complete if Known
Application Number	08/974,584
Filing Date	November 19, 1997
First Named Inventor	
Art Unit	1634
Examiner Name	Myers, Carla J.
Attomey Docket Number	015389-002950US

-		1	U.S. PATENT DO	1	
_	Document Number			1	
Examiner Initials*	Cite No.1	Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
$C_{\Delta}$	A1	US-5,597,697	01-28-1997	Diamond	
<u></u>	A2	US-5,747,317	05-05-1998	Cao	
	A3	US-5,770,422	06-23-1998	Collins	
	A4	US-5,917,025	06-29-1999	Collins	
	A5	US-5,919,656	07-06-1999	Harrington, et al.	
	A6	US-6,166,178	12-26-2000	Cech et al.	
	A7	US-6,337,200 B1	01-08-2002	Morin	
	A8	US-6,475,789 B1	11-05-2002	Cech et al.	
	A9	US-6,610,839 B1	08-26-2003	Cech et al.	
Cr.	A10	US-6,617,110 B1	09-09-2003	Cech et al.	

		<del>-</del> , -		FOREIG	N PA	TENT DOCUME	NTS			
Examiner Initials*	Cite No. <sup>1</sup>	For Country Code <sup>3</sup>	eign Patent Docu Number <sup>4</sup>	iment Kind Code <sup>a</sup> (ii	f known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T⁰
$\alpha$	B1	GB	2 317 891	/ /	4	04-08-1998				$\beth_{\_}$
	B2	РСТ	WO 93/2357	2 / A	1	11-25-1993				卫
	В3	PCT	WO 94/1721	0 / A	.1	08-04-1994				᠋_
	B4	PCT	WO 95/1338	2 / A	11	05-18-1995			Ш	<u> </u>
	B5	PCT	WO 96/0183	5 / A	<b>\1</b>	01-25-1996				<u> </u>
	B6	PCT	WO 98/0783	8 <u>/ A</u>	\1	02-26-1998		see abstract	Ш	<u> </u>
	B7	PCT	WO 98/0893	8 A	1	03-05-1998		see abstract		<u> </u>
	B8	PCT	WO 98/1459	2 / A	2	04-09-1998			Ш	<u> </u>
	B9	PCT	WO 98/1459	3 / A	2	04-09-1998			Ш	<u>」</u>
	B10	PCT	WO 98/2134	3 / A	<b>\1</b>	05-22-1998			Ц	
	B11	PCT	WO 98/2375	9 / A	2	06-04-1998			$\perp$ !	<u> </u>
	B12	PCT	WO 98/3718	1./ A	2	08-27-1998			Ц	<u> </u>
	B13	PCT	WO 98/4545	0 / A	<u></u>	10-15-1998		<u> </u>	Ц	<u> </u>
	B14	PCT	WO 98/5904	0 / A	.2	12-30-1998			$\perp$	ᆜ
	B15	PCT	WO 99/0156	0 / <u>A</u>	\1	01-14-1999			Ц	ᆜ
	B16	PCT	WO 99/3399	8 / A	2	07-08-1999			Ц	ᆜ
	B17	PCT	WO 99/3896	4 / A	12	08-05-1999			Ц	<u> </u>
J/	B18	PCT	WO 00/4635	i5 / A	١2	08-10-2000				<u>ப</u>

Examiner Signature	CHIAN	Date Considered	5-16-06
	( MUNKY	Considered	J- 16 9-

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. A Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 5

Complete If Known				
Application Number	08/974,584			
Filing Date	November 19, 1997			
First Named Inventor				
Art Unit	1634			
Examiner Name	Myers, Carla J.			
Attorney Docket Number	015389-002950US			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
Cr	C1	ADAMSON, D. et al. "Significant Telomere Shortening in Childhood Leukemia", Cancer Genet. Cytogenet, 1992; pp. 204-206, Vol. 61	
	C2	AUTEXIER, CHANTAL, et al., "Telomerase and cancer: revisiting the telomere hypothesis; Trends in Biochemical Sciences, 1996, pp. 387-391, Vol. 10, No. 21.	
	СЗ	AVILION, A., "Characterization and expression of human telomerase," Dissertation Abstracts International", 1996, pp. 5930-8, Vol. 56, No. 11	
	C4	BARINGA, MARCIA, "The Telomerase Picture Fills In", Science, April 25, 1997; pp. 528-529, Vol. 276	1
	C5	CHIU, et al. "Replicative senescence and cell immortality: the role of telomeres and telomerase (44075)", <i>Proc. Soc. Exp. Bio. Med.</i> , 1997, pp. 99-106, Vol. 214.	
	C6	CHONG, L. et al. "A Human Telomeric Protein", Science, Dec. 1995, pp. 1663-1667, Vol. 270.	
	C7	COLLINS, KATHLEEN, "Structure and function of telomerase", Current Opinion in Cell Biology, 1996, pp. 374-380, Vol. 8	
	С8	COUNTER, C. et al. "Telomerase activity in human ovarian carcinoma"; <i>Proc. Natl. Acad. Sci USA</i> ; April 1994; Vol. 91; pp. 2900-2904 ./	
	C9	COUNTER, C. et al. "Telomerase Activity in Normal Leukocytes and in Hematologic Malignancies" Blood; May 1, 1995; pp. 2315-2320, Vol. 85, No. 9.	
	C10	COUNTER, C. et al. "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity", <i>The EMBO Journal</i> ; 1992, pp. 1921-1929, Vol. 11; No. 5, Oxford University Press.	
	C11	DE LANGE, T. et al. "Structure and Variability of Human Chromosome Ends"; <i>Molecular and Cellular Biology</i> ; February 1990; pp. 518-527, Vol. 10, No. 2	
	C12	FENG et al., "The RNA Componant of Human Telomerase," Science, 1995, pp. 1236-1241, Vol. 269	1
	C13	FLAVELL, R. & MATHIAS, R. "Prospects for transforming monocot crop plants", <i>Nature</i> , 12 Jan. 1984, pp. 108-109, Vol. 307.	
	C14	FRESHNEY, Culture of Animal Cells, A Manual Basic Technique, p. 4, Alan R. Liss, Inc. New York, 1983.	
	C15	Genbank Accession No. A46242; September 21, 1993 /	
V	C16	Genbank Accession No. AA299878; April 18, 1997	

Examiner Signature	Cherry	Date Considered	5-14-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

TO 8 TOTAL SUCCESSION SUCCESSION

iuestitute for form 14498/PTO

# MIFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known				
Application Number	08/974,584			
Filing Date	November 19, 1997			
First Named Inventor				
Art Unit	1634			
Examiner Name	Myers, Carla J.			
Attorney Docket Number	015389-002950US			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
Con	C17	Genbank Accession No. AA311750; April 19, 1997		
	C18	Genbank Accession No. L38903; January 30, 1995		
	C19	Genbank Accession No. Q06163; November 01, 1995		
	C20	Genbank Accession No. S39696; October 07, 1994		
	C21	Genbank Accession No. S53396; May 5, 1995		
	C22	GenBank Accession No. W70315; June 19, 1996		
	C23	GLASER, P. et al. "Bacillus subtilis genome project: cloning and sequencing of the 97 kb region from 325° to 333°" <i>Molecular Microbiology</i> , 1993, pp. 371-384, Vol. 10, No. 2.		
	C24	GOODMAN, R. et al. "Gene Transfer in Crop Improvement", Science, 3 April 1997, pp. 48-54, Vol. / 236.		
	C25	GREIDER, C. "Telomeres, Telomerase and Senescence"; <i>BioEssays</i> ; 1990; pp. 363-369, Vol. 12, No. 8.	_	
•	C26	HARLEY, C. "Telomere loss: Mitotic clock or genetic time bomb?" <i>Mutation Research</i> ; 1991; pp. 271-282, Vol. 256, Elsevier Science Publishers.		
	C27	HARLEY, C. & VILLEPONTEAU, B. "Telomeres and telomerase in aging and cancer" Current Opinion in Genetics and Development; 1995, pp. 249-255, Vol. 5.		
	C28	HARLEY, C. et al. "Telomeres shorten during ageing of human fibroblasts", <i>Nature</i> , 31 May 1990; pp. 458-460, Vol. 345.		
	C29	HASTIE, N. et al. "Telomere reduction in human colorectal carcinoma and with ageing", Nature, 30 August 1990, pp. 866-868, Vol. 346.		
	C30	HEALY, K. C. "Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy" Oncol. Res., 1995, pp. 121-130, Vol. 7		
	C31	HENDERSON, C. Cancer genetics gene regulates telomerase resulting in death of cancer cells; Gene Therapy Weekly, 11 September 1995.		
	C32	HIYAMA, E. et. al. "Correlating telomerase activity levels with human neuroblastoma outcomes"; Nature Medicine; 3 March 1995; pp. 249-255, Vol. 1, No. 3.	-	
1	C33	HOLTZMANN, K. et al. "Telomeric Associations and Loss of Telomeric DNA Repeats in Renal Tumors", Genes, Chromosomes & Cancer, 1993, pp. 178-181, Vol. 6.		

Examiner Signature	Church	Date Considered	5-16-06	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

ute for form 1449B/PTO

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known			
Application Number 08/974,584			
Filing Date	November 19, 1997		
First Named Inventor			
Art Unit	1634		
Examiner Name	Myerş, Carla J.		
Attorney Docket Number	015389-002950US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
Con	C34	JÄHNE, A. et al. "Genetic Engineering of Cereal Crop Plants: A Review", Euphytica, 1995, pp. 35-44, Vol. 85, Kluwer Academic Publishers, Netherlands.	
1	C35	JOHNSON, P. et al., "Expression of Wild-Type p53 Is Not Compatible with Continued Growth of p53-Negative Tumor Cells", <i>Molecular and Cellular Biology</i> , Jan. 1991, p. 1-11, Vol. 11, No. 1.	
	C36	JOLLIFFE, L.K. "Humanized antibodies: enhancing therapeutic utility through antibody engineering", Int. Rev. Immunol., 1993, pp. 241-250, Vol. 10	
	C37	KIM, N. et al. "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer", Science, 23 December 1994, pp. 2011-2014, Vol. 266.	
	C38	KLINGELHUTZ, A. et al. "Restoration of Telomeres in Human Papillomavirus- Immortalized Human Anogenital Epithelial Cells"; Molecular and Cellular Biology, Feb. 1994, pp. 961-969, Vol. 14, No. 2.	
	C39	LEWIS, A. & CROWE, J.S. "Generation of humanized monoclonal antibodies by 'best fit' framework selection and recombinant polymerase chain reaction", Year Immunol., 1993, pp. 110-118, Vol. 7	
	C40	Linking telomerase and tumors; Genesis Report- Dx; 1995; Vol. 4, No. 6; Publisher Genesis Group Associates.	
	C41	LUNDBLAD, V. & BLACKBURN, E., Letter to the Editor entitled, "RNA-Dependent Polymerase Motifs in EST1: Tentative Identification of a Protein Component of an Essential Yeast Telomerase", Cell, 23 Feb. 1990, pp. 529-530, Vol. 60.	
	C42	LUSTIG, ARTHUR J., "The identification of telomerase subunits: catalysing telomere research", Trends in Cell Biology; August 1997, pp. 299-302, Vol. 7.	
	C43	MALICKI, J. et al. "A human HOX4B regulatory element provides head-specific expression in Drosophila embryos", Nature, 23 July 1992, pp. 345-357, Vol. 358.	
	C44	NAKAYAMA, J. et al. "Cloning of a Candidate cDNA Encoding a Proteinaceous Component of Mammalian Telomerase", <i>Molecular Biology Cell Abstracts Supp.</i> 7, 1996, p. 875-884, 286a Section 1664.	
	C45	NATARAJAN et al. "Major histocompatibility complex determinants select T-cell receptor alpha chain variable region dominance in a peptide-specific response." <i>Proc. Natl. Acad. Sci.</i> , Oct 1992, pp. 8874-8878, Vol. 19.	
	C46	PASZKOWSKI, JERZY et al. "Direct gene transfer to plants," The EMBO Journal, 1984, pp. 2717-2722, Vol. 3, No. 12.	
	C47	POTRYKUS, I. et al. "Direct gene transfer to cells of a graminaceous monocot", Mol. Gen. Genet., 1985, pp. 183-188, Vol. 199.	
	C48	RAYMOND, E., et al.; Agents that target telomerase and telomeres; Curr. Opin. Biotechnol.; 1996; 7:583-91	

Examiner Signature	Church	Date Considered	5-16-06
			<u>l                                     </u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute Substitute

Substitute for form 1449B/PTO

# 外FORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known			
Application Number	08/974,584		
Filing Date	November 19, 1997		
First Named Inventor			
Art Unit	1634		
Examiner Name	Myers, Carla J.		
Attorney Docket Number	015389-002950US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Con	C49	RHYU, M.S. "Telomeres, telomerase, and immortality"; J. Natl. Cancer Inst.; 21 June 1995; pp. 884-894, Vol. 87, No. 12.	
	C50	SCHENA et al. "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes", Proc. Natl. Acad. Sci., Oct. 1996, pp. 10614-10619, Vol. 93, USA.	
	C51	SCHWARTZ, H. et al. "Telomere Reduction in Giant Cell Tumor of Bone and with Aging"; Cancer Genet Cytogenet; 1993; pp. 132-138, Vol. 71, Elsevier Science Publishing Co., Inc., New York, U.S.A,	
	C52	SINGER, M. "Unusual Reverse Transcriptases", Journal of Biological Chemistry; 1995, pp. 24623-23626, Vol. 270, No. 42	
	C53	SMITH, J. & YEH, G. "Telomere Reduction in Endometrial Adenocarcinoma"; Am. J. Obstet. Gynecol.; Dec. 1992; pp. 1883-1887, Vol. 167, No. 6	
	C54	TAIT, J. et al. "Structure and Polymorphisms of the Human Annexin III (ANX3) Gene", Genomics, 1993, pp. 79-86, Vol. 18, No. 1	
	C55	WINTER, G. & HARRIS, W. "Humanized Antibodies", <i>Trends Pharmacol. Sci.</i> , May 1993, pp. 139-143, Vol. 14.	
	C56	WIRTH, URS et al; "Immediate-Early RNA 2.9 and Early RNA 2.6 of Bovine Herpesvirus 1 Are 3' Coterminal and Encode of Putative Zinc Finger Transactivator Protein"; <i>Journal of Virology</i> ; May 1992; pp. 2763-2772, Vol. 66, No. 5.	
\ <u></u>	C57	ZAUG, ARTHUR et al., "Method for determining RNA 3' ends and application to human telomerase RNA", Nucleic Acids Research, 1996, pp. 532-533, Vol. 24, No. 3.	

Examiner	$\rho$	Date	
Signature	/ L		5. 16.06
Signature		Considered	3.7008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.